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PPRECLINICAL RESEARCH
Lipopolysaccharide Activates
Calcineurin in Ventricular Myocytes
Jun Suzuki, MD, PHD,*† Evelyn Bayna, PHD,* Hai Ling Li, PHD,* Erminia Dalle Molle, BS,*†
Wilbur Y. W. Lew, MD, FACC*†
San Diego, California
Objectives We investigated whether lipopolysaccharide (LPS), a proximate cause of inflammation, activates calcineurin in
cardiac myocytes and if calcineurin regulates apoptosis in this setting.
Background Calcineurin regulates myocardial growth and hypertrophy, but its role in inflammation is unknown. Calcineurin
has proapoptotic or antiapoptotic effects depending on the stimuli.
Methods Calcineurin activity was measured in left ventricular myocytes from adult Sprague Dawley rats. Cardiac apopto-
sis was measured by terminal deoxy-nucleotidyl transferase-mediated dUTP nick end-labeling staining and
caspase-3 activity after in vitro and in vivo exposure to LPS.
Results Lipopolysaccharide increased calcineurin activity in myocytes over 1 to 24 h (t 1/2  4.8 h) with an EC50 of
0.80 ng/ml LPS (p  0.05, n  4). The LPS (10 ng/ml) effects were mimicked by angiotensin II (Ang II) (100
nmol/l); both increased calcineurin activity and induced apoptosis without additive effects (p 0.05, n  5 to 9).
Lipopolysaccharide and/or Ang II effects were prevented by 1 h pre-treatment with an Ang II type 1 receptor
blocker (losartan, 1 mol/l), calcineurin inhibitor (cyclosporin A, 0.5 mol/l), calcium chelator (1,2-Bis(2-amino-
5-fluorophenoxy)ethane-N,N,N=,N=-tetraacetic acid tetrakis(acetoxymethyl) ester, 0.1 mol/l), or by inhibiting
sarcoplasmic reticulum (SR) calcium (Ca)-ATPase (thapsigargin, 1 mol/l) or SR calcium release channel (ryano-
dine, 1 mol/l). Left ventricular apoptosis increased from 4 to 24 h after LPS (1 mg/kg intravenously) in vivo,
but not in rats pre-treated with cyclosporin A (20 mg/kg/day subcutaneously) for 3 days (p  0.05, n  5).
Conclusions In cardiac myocytes, LPS activates calcineurin in association with apoptosis by Ang II and SR calcium-dependent
mechanisms. This expands the paradigm for cardiac calcineurin to be activated by low levels of LPS in inflam-
mation and chronic conditions (e.g., infections, smoking, and heart failure). (J Am Coll Cardiol 2007;49:491–9)
© 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.10.043t
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ralcineurin is an important mediator of cardiac growth and
ypertrophy (1,2). The stress signals that activate cardiac
alcineurin in physiological and pathophysiological condi-
See page 500
ions, such as pressure overload and ischemia, have been
tudied extensively. However, little is known about the role
f calcineurin in inflammation. Inflammation contributes to
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006, accepted September 1, 2006.he pathogenesis of atherosclerosis and vascular events (3)
nd may contribute to the progression of heart failure (4). It
s unknown if inflammation activates calcineurin in cardiac
yocytes.
Lipopolysaccharide (LPS) from gram negative bacteria
s one of the most common causes of inflammation and
he best characterized activator of innate immunity (5,6).
ow levels of LPS may mediate vascular inflammation in
therosclerosis (7). Cells sense minute amounts of LPS
hrough Toll-like receptor-4 (TLR-4), an LPS receptor
hat recognizes pathogen-associated molecular patterns
nd is required for cell signaling. Cardiac myocytes
xpress TLR-4 (8), although they are not professional
ells involved in innate immunity. Studies from this
aboratory demonstrated that LPS directly activates car-
iac myocytes to depress contractility (9) and induce
poptosis (10), independently of secondary mediators
eleased by non-myocytes. This occurs with low levels of
PS comparable to those found circulating in subacute
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chronic infections, smoking,
and heart failure (11–13).
The goal of this study was to
determine if LPS activates cal-
cineurin in cardiac myocytes. This
would expand the list of known
activators of cardiac calcineurin to
include inflammation, along with
previously established conditions of
cardiac growth, hypertrophy, and
ischemia-reperfusion. Calcineurin
may be activated by LPS in macro-
phages (14), but it is unknown if
LPS activates calcineurin in cardiac
myocytes.
Calcineurin is a serine/thre-
onine protein phosphatase that is
activated by a sustained increase
in calcium. Lipopolysaccharide
increases intracellular calcium in
cardiac myocytes (15,16). It is
nknown if this is sufficient to activate calcineurin, which
ay depend on specialized pools of calcium at specific
ntracellular sites (17,18). Several sites for activating calcium
ave been proposed, but none have been proven experimen-
ally (17). We hypothesized that LPS activates calcineurin
ith calcium cycling through the sarcoplasmic reticulum
SR). The rationale is that the SR plays a central role for
alcium handling and there is a physical and functional
ssociation between calcineurin and the SR calcium release
hannel or ryanodine receptor (RyR) (19,20). The cal-
ineurin inhibitor FK506 targets FK506 binding proteins,
hich regulate RyR function (21).
A secondary goal was to determine if calcineurin plays a
egulatory role to enhance or inhibit cardiac apoptosis
nduced by LPS. Calcineurin enhances cardiac apoptosis
nduced by beta-adrenergic stimulation (22), but inhibits
poptosis induced by oxidative stress or ischemia-
eperfusion (23,24). Calcineurin can induce or inhibit apo-
tosis in the same cell depending on the concurrent activa-
ion of downstream signaling pathways (25,26). Thus, the
ffects of calcineurin on apoptosis are stimuli and context-
ependent. As a subsidiary goal, we evaluated if calcineurin is
ctivated by the same cell signaling pathway as LPS-induced
poptosis, which we found to be mediated by activating cardiac
enin-angiotensin to stimulate angiotensin II type 1 (AT1)
eceptors (10,27). Angiotensin II (Ang II) increases cal-
ineurin in cardiac myocytes (28,29).
This study demonstrates that LPS activates calcineurin in
ssociation with apoptosis in cardiac myocytes. This occurs
ith low levels of LPS found in chronic conditions. This
rovides a unique link between inflammation activated by
PS, and calcineurin, an important signaling pathway for
Abbreviations
and Acronyms
Ang II  angiotensin II
AT1  angiotensin II type 1
receptor
BAPTA-AM  1,2-Bis(2-amino-
5-fluorophenoxy)ethane-
N,N,N=,N=-tetraacetic acid
tetrakis(acetoxymethyl)
ester
LPS  lipopolysaccharide
MPT  mitochondrial
permeability transition pore
RyR  ryanodine receptor
SR  sarcoplasmic
reticulum
TLR-4  Toll-like receptor-4
TUNEL  terminal deoxy-
nucleotidyl transferase-
mediated dUTP nick
end-labelingyocardial growth and hypertrophy. wethods
xperiments were performed in accordance with institu-
ional guidelines and the National Institutes of Health
Guide for the Care and Use of Laboratory Animals”
ublished by the U.S. National Institutes of Health (NIH
ublication No. 85-23, revised 1996).
ardiac myocyte preparation and protocols. Cardiac
yocytes were isolated from adult Sprague Dawley rats (250
o 400 g, either gender), as previously described (10). In
rief, rats were anesthetized with 40 mg/kg sodium pento-
arbital intraperitoneally. The heart was excised and per-
used with 15 to 30 mg/kg of depyrogenated collagenase B
nd protease containing 0.3 to 0.5 ng/ml LPS (Limulus
mobocyte lysate test QCL-1000, BioWhittaker, Walkers-
ille, Maryland) (30). Freshly isolated myocytes were plated
n dishes pre-coated with laminin in a Dulbeccos modified
agle’s media and stored at 37°C in 5% CO2 (10).
Myocytes were incubated with LPS (Escherichia coli 055,
PS no. B5, lot 2039F, List Biological Laboratories,
ampbell, California) and/or Ang II, preceded by 1 h
xposure to inhibitors including losartan (AT1 receptor
nhibitor, a kind gift from Merck and DuPont, Rahway,
ew Jersey), 1,2-Bis(2-amino-5-fluorophenoxy)ethane-
,N,N=,N=-tetraacetic acid tetrakis(acetoxymethyl) ester
BAPTA-AM) (calcium chelator), thapsigargin (SR cal-
ium ATPase inhibitor), ryanodine (SR calcium release
hannel inhibitor, Calbiochem, San Diego, California),
yclosporin A (calcineurin inhibitor), or nicotine (an inhib-
tor of LPS-induced cardiac apoptosis) (27) (unless other-
ise noted, all reagents from Sigma Chemical, St. Louis,
issouri).
alcineurin and apoptosis assays in cardiac myocytes and
eft ventricle. Calcineurin assays were performed on car-
iac myocytes harvested after 16 h of incubation. After cell
ysis, cellular calcineurin (PP2B) phosphatase activity was
easured using a BIOMOL GREEN Calcineurin Assay
it (BIOMOL Research Laboratories, Plymouth Meeting,
ennsylvania). Ethylene glycol bis(2-aminoethyl ether)-
,N,N=,N=,-tetraacetic acid (EGTA) was used as the cal-
ineurin inhibitor, and results were expressed as Total 
GTA phosphate nmol/g total protein. Protein content
as determined using a standard colorimetric assay (BCA,
ierce Chemical, Rockford, Illinois). The calcineurin activ-
ty data were fit to curves using GraphPad Prism, version
.0 from GraphPad Software, Inc. (San Diego, California).
Apoptosis was assessed in cardiac myocytes fixed with 4%
ormalin phosphate-buffered saline after 24 h of incubation.
erminal deoxy-nucleotidyl transferase-mediated dUTP
ick end-labeling (TUNEL) assays were performed using a
ardioTACS In Situ Apoptosis Detection kit (R&D Sys-
ems). At least 2,000 cells were scored from each group with
he observer blinded to the treatment condition.
In vivo studies were performed in rats injected with LPS
1 mg/kg) or saline into a tail vein (10). After 24 h, the heart
as excised and fixed in 3.7% formaldehyde solution for
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erformed on 5-m cross-section slices to determine the
verage transmural rate of TUNEL-positive stained cardi-
myocyte nuclei per 106 nuclei, measured across the left
entricular anterior, midventricular free wall, as previously
escribed (10). The time course for apoptosis was assessed
n hearts harvested immediately (time 0), 2, 4, 6, 8, or 24 h
fter injecting LPS (1 mg/kg intravenously). Caspase-3
ctivity was measured in the left ventricle with a FluroAce
popain Assay Kit (Bio-Rad Laboratories, Richmond,
alifornia).
tatistical analysis. Results were compared by 1- or 2-way
epeated measures analysis of variance (ANOVA) in proto-
ols where myocytes from each rat were subdivided into
eparate dishes to test individual treatments (n  1 for each
at heart). Left ventricular data from different animals were
nalyzed by 1- or 2-way ANOVA. Post-hoc comparisons
ere performed with Student-Newman-Keuls methods. All
esults are expressed as mean  SE. Statistical significance
ndicates p  0.05. The statistical analyses were performed
ith SigmaStat Statistical Software, version 2.0 from SPSS
cience (Chicago, Illinois).
Figure 1 Time Course and LPS Dose Dependence
of Calcineurin Activity in Cardiac Myocytes
(A) Calcineurin activity in cardiac myocytes (mean  SE, n  4) increased
with lipopolysaccharide (LPS) (10 ng/ml) compared with control (vehicle) after 1 to
24 h, with t 1/2 of 4.8 h (p  0.05). (B) Lipopolysaccharide dose-calcineurin
activity relationship (mean  SE, n  4). After 16 h incubation with LPS, cal-
cineurin activity increased in cardiac myocytes with an EC50 of 0.80 ng/ml LPS
(p  0.05).wesults
PS increases calcineurin activity in cardiac myocytes.
ardiac myocytes were incubated with LPS (10 ng/ml) or
ehicle. Figure 1A shows time-calcineurin activity data
mean with SE bars, n  4 for each treatment at each time
oint) fit to a 1-phase exponential curve. After 1, 2, 4, 8, 16,
nd 24 h, there was a significant increase in calcineurin
ctivity with LPS, but not in vehicle-treated myocytes (p 
.05, 2-way repeated measures ANOVA, p  0.001 for
nteraction between LPS and time). Although the sample
ize was small, when the repeated measures ANOVA was
erformed using the conservative Greenhouse-Geisser ad-
ustment, the interaction between LPS and time remained
ignificant (p  0.013). Calcineurin activity increased with
half-time of 4.8 h after LPS, with a maximum response of
.19 nmol/g protein.
The LPS dose-calcineurin activity relationship was de-
ermined in cardiac myocytes incubated with 0.01 ng/ml
1011 g/ml) to 100 ng/ml (107 g/ml) LPS for 16 h.
igure 1B shows data fit to a sigmoidal curve (n  4 each
ose, mean with SE bars). There was higher calcineurin
ctivity with 1, 10, and 100 ng/ml LPS compared with 0.01
r 0.1 ng/ml LPS (p  0.05, 1-way repeated measures
NOVA). Calcineurin activity increased with an EC50 of
.80 ng/ml LPS.
ell signaling pathways for LPS activation of cal-
ineurin. It was determined if LPS activation of cal-
ineurin involves the same AngII and AT1 receptor-
ediated pathways as LPS-induced cardiac apoptosis (10).
ardiac myocytes were incubated for 16 h with or without
PS (10 ng/ml) and/or Ang II (100 nmol/l). This also was
erformed in myocytes pre-treated for 1 h with losartan (1
mol/l). Figure 2 shows that both LPS and Ang II increased
alcineurin activity without additive effects (p  0.001, 1-way
epeated measures ANOVA, n  6). The calcineurin activity
ith LPS  Ang II combined was less than with Ang II
lone (p  0.05), but did not differ compared with LPS
lone. Neither LPS nor Ang II increased calcineurin activity
n the presence of losartan.
Cyclosporin A is a potent and specific inhibitor of cal-
ineurin (31). Calcineurin is a calcium-dependent phosphatase
hat is inhibited by the calcium chelator BAPTA-AM. To
valuate if the source of calcium for activating calcineurin cycles
hrough the SR, thapsigargin, a Ca-ATPase inhibitor, was
sed to inhibit SR calcium re-uptake. Myocytes were incu-
ated with vehicle (control) or LPS (10 ng/ml) for 16 h, with
r without 1 h of pre-treatment with inhibitors. Figure 3A
emonstrates that LPS increased calcineurin activity, which
as blocked by either cyclosporin A (0.5 mol/l),
APTA-AM (0.1 mol/l), or thapsigargin (1 mol/l) (p 
.05, 1-way repeated measures ANOVA, n  5).
To confirm an SR role, SR calcium cycling was inhibited
t a different site using ryanodine, an inhibitor of the SR
alcium release channel. Cardiac myocytes were incubated
ith vehicle (control) or LPS (10 ng/ml) for 16 h, with or
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Lipopolysaccharide Activates Cardiac Calcineurin January 30, 2007:491–9ithout 1-h pre-treatment with ryanodine (1 mol/l, 1 h
efore LPS), which locks the SR calcium release channel in
n open state (32). Figure 3B shows that ryanodine inhib-
ted LPS-induced increase in calcineurin activity (p  0.05,
-way repeated measures ANOVA, n  6).
Figure 3B shows that pre-treatment of myocytes with
icotine (15 ng/ml, 4 h before LPS), which inhibits LPS-
nduced apoptosis (27), prevented increased calcineurin
ctivity with LPS (p  0.005, n  6).
PS activation of calcineurin is associated with apoptosis.
o determine if calcineurin induces or inhibits cardiac
poptosis with LPS, cardiac myocytes were incubated for
4 h with or without LPS (10 ng/ml) and the calcineurin
nhibitor cyclosporin A (0.5 mol/l, 1 h before LPS). We
reviously observed peak changes in TUNEL staining to
ccur 24 h after LPS in this model (10). Figure 4A
emonstrates that cyclosporin A blocked an LPS-induced
ncrease in TUNEL staining (p  0.05, 2-way repeated
easures ANOVA, n  7). For comparison, a similar
rotocol was performed in myocytes incubated for 24 h with
r without Ang II (100 nmol/l) and cyclosporin A (0.5
mol/l, 1 h before Ang II). Figure 4B shows that cyclosporin
also blocked increased TUNEL staining with Ang II (p 
.05, n  9).
Similar results were obtained with other inhibitors of
PS-induced calcineurin activation. Cardiac myocytes were
ncubated for 24 h with or without LPS (10 ng/ml) or Ang
I (100 nmol/l), with or without pre-treatment with
APTA-AM (0.1 mol/l, 1 h before LPS or Ang II). In
igure 5A, BAPTA-AM prevented increased TUNEL
taining with LPS or Ang II (p  0.05, 1-way repeated
easures ANOVA, n  5). In a separate protocol, cardiac
Figure 2 Calcineurin Activity in Cardiac Myocytes
With LPS and/or Ang II Inhibited by Losartan
Calcineurin activity in cardiac myocytes (mean  SE, n  6) increased after
16-h incubation with lipopolysaccharide (LPS) (10 ng/ml) and/or angiotensin II
(Ang II) (100 nmol/l) without cumulative effects (p  0.05). This was blocked by
pre-treating myocytes with losartan (1 mol/l, Ang II type 1 receptor inhibitor) 1 h
before LPS or Ang II, while losartan alone had no effect.yocytes were incubated for 24 h with or without LPS (10g/ml) or Ang II (100 nmol/l), with or without pre-
reatment with thapsigargin (1 mol/l, 1 h before LPS or
ng II). In Figure 5B, thapsigargin blocked increased
UNEL staining with LPS or Ang II (p  0.05, 1-way
epeated measures ANOVA, n  9). Thus, interventions
hat inhibited LPS-induced calcineurin activation, includ-
ng cyclosporin A, BAPTA-AM, thapsigargin, losartan,
nd nicotine, also prevented LPS and Ang II induced
poptosis. This supports a proapoptotic effect of calcineurin
ctivated by LPS.
PS-induced left ventricular apoptosis in vivo. The time
ourse for LPS-induced apoptosis was measured in vivo.
igure 6 shows caspase-3 activity in the left ventricle (mean
E) immediately (time 0, n 18), 2 h (n 11), 4 h (n
1), 6 h (n  7), 8 h (n  11), and 24 h (n  19) after
njecting LPS (1 mg/kg intravenously) in vivo. Caspase-3
Figure 3 Cyclosporin A, BAPTA-AM, TG, Ryanodine, or
Nicotine Inhibit LPS-Induced Calcineurin Activity
Calcineurin activity in cardiac myocytes (mean  SE) increased after 16-h incuba-
tion with lipopolysaccharide (LPS) (10 ng/ml) compared with control (vehicle) (p 
0.05). (A) This was blocked by pre-treating myocytes (1 h before LPS) with
either cyclosporin A (0.5 mol/l), 1,2-Bis(2-amino-5-fluorophenoxy)ethane-
N,N,N=,N=-tetraacetic acid tetrakis(acetoxymethyl) ester (BAPTA-AM) (0.1 mol/
l), or thapsigargin (TG) (1 mol/l) (n  5). (B) Lipopolysaccharide effects were
blocked by pre-treating myocytes with ryanodine (1 mol/l, 1 h before LPS), or
nicotine (15 ng/ml, 4 h before LPS) (n  6).
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January 30, 2007:491–9 Lipopolysaccharide Activates Cardiac Calcineurinctivity increased from 4 to 24 h after LPS (p  0.05 vs.
ime 0, 1-way ANOVA). This is consistent with the time
ourse for LPS to increase calcineurin activity in cardiac
yocytes in vitro (Fig. 1A).
The role of calcineurin in vivo was examined by treating
ats with cyclosporin A (20 mg/kg/day subcutaneously) for
days before injecting LPS (1 mg/kg) by tail vein. This
ose of LPS induces cardiac apoptosis without causing
istress or affecting blood pressure (10,27). Figure 7 shows
UNEL staining in the left ventricle in 4 groups of rats
n  5 per group) 24 h after intravenous injections of: 1)
aline (control); 2) LPS; 3) saline after 3 days pre-treatment
ith cyclosporin A (cyclosporin A); or 4) LPS after 3 days
Figure 4 LPS- or Ang II-Induced TUNEL Staining
in Cardiac Myocytes Inhibited by Cyclosporin A
Terminal deoxy-nucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL)
staining of cardiac myocytes (mean %  SE) increased after 24 h with lipopoly-
saccharide (LPS) (10 ng/ml, n  7) (A) or angiotensin II (Ang II) (100 nmol/l,
n  9) (B) compared with control (vehicle) (p  0.05). In both cases, this was
blocked by the cyclosporin A (0.5 mol/l, 1 h before LPS or Ang II), while cyclo-
sporin A alone had no effect (p  0.05).re-treatment with cyclosporin A (LPS  cyclosporin A).njecting LPS increased TUNEL staining compared with
ontrol, but not in rats pre-treated with cyclosporin A (p 
.05, 2-way ANOVA, n  5).
iscussion
he major finding in this study is that LPS activates cal-
ineurin in cardiac myocytes, and in this setting, calcineurin has
roapoptotic effects. Cardiac calcineurin was activated within
ours (t 1/2  5 h) by low levels of LPS (EC50  0.8 ng/ml)
hat are relevant for subacute and chronic conditions. This
as associated with apoptosis that was blocked by the
alcineurin inhibitor cyclosporin A in cardiac myocytes in
itro, as well as in the left ventricle in vivo. Calcineurin
Figure 5 LPS- or Ang II-Induced TUNEL Staining of Cardiac
Myocytes Inhibited by BAPTA-AM or Thapsigargin
Terminal deoxy-nucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL)
staining of cardiac myocytes (mean %  SE) increased after 24 h with lipopoly-
saccharide (LPS) (10 ng/ml) or angiotensin II (Ang II) (100 nmol/l) compared
with control (vehicle) (p  0.05). This was blocked by pre-treating myocytes 1 h
before LPS or Ang II with: (A) 1,2-Bis(2-amino-5-fluorophenoxy)ethane-
N,N,N=,N=-tetraacetic acid tetrakis(acetoxymethyl) ester (BAPTA-AM) (0.1 mol/
l), while BAPTA-AM alone had no effect (n  5); (B) Thapsigargin (TG) (1 mol/
l), while TG alone had no effect (n  9).
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Lipopolysaccharide Activates Cardiac Calcineurin January 30, 2007:491–9ctivation was inhibited by the calcium chelator BAPTA-
M, SR Ca-ATPase inhibitor thapsigargin and SR RyR
nhibitor ryanodine, indicating that the activating calcium
or calcineurin is SR-dependent. Calcineurin activation was
imicked by Ang II without cumulative effects, and blocked
y losartan (AT1 receptor inhibitor), similar to the pathway
hat we demonstrated to mediate LPS-induced apoptosis
10). Calcineurin activation was inhibited by nicotine,
hich inhibits LPS-induced apoptosis proximal to AT1
eceptor activation (27). The simultaneous inhibition of
poptosis with multiple inhibitors of calcineurin, including
yclosporin A, BAPTA-AM, thapsigargin, losartan, and
icotine indicates that calcineurin has proapoptotic effects in
he context of LPS.
Low levels of LPS have direct effects on cardiac myocytes
9,10) mediated through TLR4 (8) that are distinct from
he cardiotoxic effects that occur when high levels of LPS
ctivate a cascade of mediators in sepsis (33). Circulating
PS levels in the pg/ml to low ng/ml range occur in
ecompensated heart failure (12), periodontitis (34),
hronic infections (e.g., lung, urinary tract), smoking (13),
emodialysis, cirrhosis, pancreatitis, abdominal and cardio-
horacic surgery (11). Thus, LPS may activate calcineurin in
variety of clinical scenarios. Calcineurin has proapoptotic
ffects with LPS, similar to its role with beta-adrenergic
timulation (22), whereas calcineurin has primarily anti-
poptotic effects in hypertrophy (2) and ischemia-
eperfusion (23,24).
Chronic activation of calcineurin by LPS may contribute
o the progression of pre-existing heart disease since the
eart has a limited capacity to compensate for the loss of
ardiac myocytes by apoptosis. In support of this postulate,
hronic low levels of apoptosis induce heart failure (35), and
ransgenic mice that overexpress calcineurin have depressed
Figure 6 Time Course for Caspase-3 Activity
in Left Ventricle After LPS In Vivo
Caspase-3 activity in the left ventricle increased from control (time  0) 4 to
24 h after injecting lipopolysaccharide (LPS) (1 mg/kg intravenously) in vivo
(p  0.05, mean  SE, each bar n  7 to 19).ardiac function (after an initial hypertrophy phase) withecreased survival (36). Recurrent LPS exposure may occur
ith episodes of decompensated heart failure (12) or with
hronic infections such as periodontitis (34). Chronic expo-
ure to low levels of LPS has systemic effects. In periodon-
itis, markers of inflammation (37,38) and carotid arterial
ntima media wall thickness (39,40) increase. The effects of
hronic LPS exposure on cardiac myocytes, which express
he LPS receptor TLR4, have not been examined.
Cyclosporin A may inhibit apoptosis by mechanisms
nrelated to calcineurin inhibition. Cyclosporin A inhibits
itochondrial cytochrome c release and caspase activation
h after LPS in an isolated heart model (41). Cyclosporin
inhibits the mitochondrial permeability transition pore
MPT) to attenuate cardiac apoptosis with oxidative stress
H2O2) (42). Although cyclosporin A inhibits MPT, several
gents with variable effects on MPT inhibited LPS-induced
alcineurin activation and apoptosis, including losartan,
APTA, thapsigargin, and nicotine (27). Losartan and
icotine do not have prominent effects on cardiac MPT,
lthough nicotine at 10- to 100-fold higher doses than used
n the current study may inhibit MPT in isolated brain
itochondria (43). Thapsigargin directly induces MPT in
ardiac myocytes at doses of 15 M, which would have
roapoptotic effects (44), whereas in the current study, 1
M thapsigargin inhibited LPS-induced activation of cal-
ineurin and apoptosis. The concordance of calcineurin and
poptotic responses over a wide range of conditions indi-
ates that calcineurin is a unique downstream marker and/or
ediator of LPS-induced apoptosis. These results, however,
o not prove that calcineurin activation is required for
PS-induced apoptosis.
Figure 7 Left Ventricle Myocyte TUNEL Staining After LPS In
Vivo Inhibited by Pre-Treating Rats With Cyclosporin A
Terminal deoxy-nucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL)
staining in the left ventricle (mean  SE, n  5) increased 24 h after in vivo
intravenous injection (tail vein) of lipopolysaccharide (LPS) (1 mg/kg) compared
with control (saline injection) (p  0.05, 2-way analysis of variance). This was
blocked by pre-treating rats with cyclosporin A (20 mg/kg/day subcutaneously
for 3 days before LPS or saline injections), while cyclosporin A treatment alone
had no effect.
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January 30, 2007:491–9 Lipopolysaccharide Activates Cardiac CalcineurinThapsigargin has other effects besides inhibiting SR
a-ATPase. Thapsigargin mobilizes calcium from endo-
lasmic reticulum stores to activate calcineurin and induce
poptosis in neural (45,46) and prostate cancer cells (47).
his is unimportant in cardiac myocytes, since thapsigargin
nhibits SR Ca-ATPase to attenuate the increase in intra-
ellular calcium with Ang II (48). Furthermore, thapsigar-
in alone did not affect apoptosis, but inhibited LPS-
nduced calcineurin activation and apoptosis in cardiac
yocytes.
Calcineurin is activated by localized increases in cal-
ium, but the intracellular site has not been experimen-
ally proven (17,18). Calcineurin is activated by low-
requency, sustained elevations in calcium, rather than by
igh-frequency, high-amplitude transient changes in cal-
ium that occur with each cardiac cycle. Postulated
ources for activating calcium include calcium entry
hrough L-type calcium channels, T-type calcium chan-
els, calcium released from the SR, and IP3R-mediated
elease of calcium stores (17,18).
The current results identify the source of activator cal-
ium as calcium cycling through the SR. Activation of
ardiac calcineurin by LPS or Ang II was prevented by
nhibiting SR calcium uptake with the SR Ca-ATPase
nhibitor thapsigargin, or by inhibiting SR calcium release
ith the RyR inhibitor ryanodine. Since the myocytes were
Figure 8 Proposed Cell Signaling Pathways for LPS-Induced Ac
Proposed cell signaling pathways for lipopolysaccharide (LPS) induced activation o
angiotensin II type 1 receptor; BAPTA-AM  1,2-Bis(2-amino-5-fluorophenoxy)ethan
lum; TLR-4  Toll-like receptor-4.on-contractile, calcineurin activation does not require de- Lolarization of L-type calcium channels or the systolic
elease of calcium from RyR. In non-contractile myocytes,
he major source of diastolic SR calcium flux is spontaneous
penings of RyR that produce calcium sparks. Since there is a
lose physical and functional association between calcineurin
nd RyR (19,20), calcium sparks may activate calcineurin in a
ocalized region at or near the RyR. This is consistent with the
oncept that cell signaling pathways may be activated by a pool
f calcium that is separate from the cytosolic calcium with
xcitation-contraction coupling (18).
The calcineurin activity with LPS  Ang II combined
as less than with Ang II alone (Fig. 2). The cause for this
mall difference is unknown, but may represent an interac-
ion between LPS and Ang-II-activated pathways. We
reviously found that LPS activates the inducible nitric
xide synthase (iNOS)-cyclic guanosine monophosphate
athway, which is important for contractile depression (9),
ut not for apoptosis (10). However, iNOS may play an
ndirect role by decreasing SR calcium release. In support of
his, LPS-activated iNOS depresses beta-adrenergic stimu-
ated ryanodine receptor function (49). A decrease in SR
alcium release may result in less calcineurin activation with
PS  Ang II combined, compared with Ang II alone.
The proposed cell signaling pathways involved in LPS
ctivation of calcineurin are summarized in Figure 8 (with
nhibitory effects shown with red lines). In the context of
on of Cardiac Calcineurin
eurin. Inhibitory effects are shown with red lines. Ang II  angiotensin II; AT1 
N=,N=-tetraacetic acid tetrakis(acetoxymethyl) ester; SR  sarcoplasmic reticu-tivati
f calcin
e-N,N,PS, calcineurin has proapoptotic effects.
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Lipopolysaccharide Activates Cardiac Calcineurin January 30, 2007:491–9In conclusion, low levels of LPS activate calcineurin in
ardiac myocytes. This involves LPS-induced activation of
he cardiac renin-angiotensin system and cardiac AT1 re-
eptors, and is mediated by SR calcium-dependent mecha-
isms. This expands the paradigm for cardiac calcineurin,
n important mediator of cardiac hypertrophy, to be acti-
ated in inflammation and chronic conditions associated
ith low circulating levels of LPS.
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